Injectables Guide Released for Florida Patients

In its newly released 2025 Global Survey, the International Society of Aesthetic Plastic Surgery reported that botulinum toxin remained the most common nonsurgical aesthetic procedure worldwide, with approximately 7.3 million procedures performed by plastic surgeons. Hyaluronic acid filler ranked second with approximately 4.7 million procedures.

The Florida-based aesthetics and wellness practice, Refresh Aesthetics & Wellness, has published a comprehensive 2026 Florida Guide to Injectables, a new patient guide that compares leading neuromodulators, FDA-approved uses, treatment differences, safety considerations, and when filler may fit. The guide addresses one of the most common questions in aesthetic medicine: Which neuromodulator is best?

According to Refresh, there is no single answer that applies to every patient. Botox, Dysport, Xeomin, and Daxxify are all prescription botulinum toxin type A products, but they are not interchangeable. They have different formulations, product-specific dosing units, FDA-approved indications, and clinical data. The appropriate choice can also depend on facial anatomy, muscle activity, treatment history, desired movement, previous response, and the specific area being treated.

The comparison comes as injectable treatments remain the dominant category in nonsurgical aesthetics. The International Society of Aesthetic Plastic Surgery reported in its newly released 2025 Global Survey that botulinum toxin remained the most common nonsurgical aesthetic procedure worldwide, with approximately 7.3 million procedures performed by plastic surgeons. Hyaluronic acid filler ranked second with approximately 4.7 million procedures.

At the same time, patients have more choices than ever. Botox, Dysport, Xeomin, and Daxxify are all prescription botulinum toxin type A products, but they are not interchangeable. They have different formulations, product-specific dosing units, FDA-approved indications, and clinical data. The appropriate choice can also depend on facial anatomy, muscle activity, treatment history, desired movement, previous response, and the specific area being treated.

The guide addresses one of the most common questions in aesthetic medicine: Which neuromodulator is best? According to Refresh, there is no single answer that applies to every patient. Botox, Dysport, Xeomin, and Daxxify are all prescription botulinum toxin type A products, but they are not interchangeable. They have different formulations, product-specific dosing units, FDA-approved indications, and clinical data. The appropriate choice can also depend on facial anatomy, muscle activity, treatment history, desired movement, previous response, and the specific area being treated.

The guide also addresses the differences between neuromodulators. All four products temporarily reduce activity in targeted muscles, but patients should not assume that one brand, dose, or price can be directly compared with another. Botox, or onabotulinumtoxinA, is one of the longest-established names in cosmetic neuromodulators. Its current U.S. cosmetic indications include moderate to severe glabellar lines between the eyebrows, lateral canthal lines commonly called crow’s feet, forehead lines, and platysma bands of the neck in appropriate adult patients. For patients asking whether Botox is still relevant as newer products enter the market, Refresh says the answer is yes. Product longevity, treatment history, and familiarity can all matter, but so can the provider's understanding of facial anatomy and appropriate dosing.

Dysport, or abobotulinumtoxinA, is FDA approved in the United States for temporary improvement of moderate to severe glabellar lines in adults younger than 65. Patients frequently compare Dysport and Botox based on unit price alone. That can be misleading. A Dysport unit is not equivalent to a Botox unit. The FDA labeling for botulinum toxin products makes clear that potency units are product specific and cannot simply be converted from one brand to another as though they were identical measurements. That means a patient seeing a lower per-unit price on one neuromodulator should not automatically conclude that the treatment itself costs less.

Xeomin, or incobotulinumtoxinA, has become a frequent topic in patient discussions because of its formulation. Xeomin contains the active neurotoxin without the accessory complexing proteins found in some other botulinum toxin formulations. Its current U.S. labeling includes temporary improvement of moderate to severe glabellar lines, horizontal forehead lines, and lateral canthal lines in adults. Refresh cautions patients against interpreting the formulation difference to mean that Xeomin is automatically "better," "cleaner," or guaranteed to prevent resistance. Neutralizing antibodies can occur with botulinum toxin therapy, but clinically meaningful resistance in aesthetic patients appears to be uncommon. If a patient believes a treatment is no longer working as expected, the cause should be evaluated rather than automatically attributed to immunity. Dose, placement, muscle strength, treatment interval, anatomy, product handling, and true immunoresistance can all be considered.

Daxxify, or daxibotulinumtoxinA-lanm, is a newer peptide-formulated neuromodulator FDA approved cosmetically for temporary improvement of moderate to severe glabellar lines in adults. It has attracted particular attention because of its duration data. In clinical research supporting Daxxify, more than half of treated subjects continued to have none or mild glabellar lines at six months based on both investigator and patient assessments.